XAIR — Beyond Air, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1641631 ·
Last close
$2.01
Market Cap
$3.35M
52W High
$53.20
52W Low
$1.85
ADV30
57,663
Next earnings
2027-02-11
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,768,000 225,000 -6,612,000 -7,935,000 32,891,000 5,509,000 30,052,000
Mar 2026 1,907,000 94,000 -7,170,000 -10,282,000 35,385,000 6,740,000 29,175,000
Dec 2025 2,194,000 300,000 -6,596,000 -7,336,000 36,774,000 6,643,000 28,488,000
Sep 2025 1,818,000 -298,000 -7,661,000 -7,940,000 30,965,000 9,699,000 17,870,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,564,000
Investing CF
$-3,789,000
Financing CF
$28,082,000
CapEx
$-1,035,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-68.40
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-327,506,000
Inventory
$1,292,000
Receivables
$1,232,000
ST Investments
$4,303,000
EBIT TTM
$-29,951,000
Pretax Income TTM
$-34,410,000
Interest Exp TTM
$4,459,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,687,000
EBITDA
$-24,796,000
Free Cash Flow
$-14,071,250
Enterprise Value
$17,146,570
Total Cash
$9,812,000
Total Debt
$23,598,000
Shares Out
1,666,104
Trailing EPS
$-64.40
Book Value
$2.69
ROE
-519.5%
ROA
-57.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 7,679,000 -29,044,000 -33,249,000 35,385,000 29,175,000 6,126,000 -18,144,000
Mar 2025 3,705,000 -44,537,000 -46,625,000 30,062,000 15,721,000 13,583,000 -38,218,000
Mar 2024 1,159,000 -63,007,000 -60,242,000 56,961,000 29,775,000 25,048,000 -56,014,000
Mar 2023 0 -52,059,000 -55,816,000 68,749,000 26,721,000 37,915,000 -33,009,000

TTM Snapshot

Revenues TTM
$7,687,000
NetIncome TTM
$-33,493,000
OpCashFlow TTM
—
Assets (Latest)
$32,891,000
Forward EPS
$-1.66

Peers — same industry

TickerNameMarket CapLastDaily %
OSRH OSR Health, Inc. $3.51M $0.10 —
BDMD Baird Medical Investment Holdings Ltd $2.94M $0.09 —
ICCM IceCure Medical Ltd. $2.84M $0.83 —
NVNO enVVeno Medical Corp $4.01M $5.77 —
TUTH Standard Dental Labs Inc. $4.10M $0.13 —

News headlines (Yahoo Finance, 1h cache)

National Advertising Division Will Refer Beyond Air to Regulatory Authorities for Declining to Participate in Self-Regulatory Process
2026-11-18 16:00 · Yahoo
Beyond Air Inc (XAIR) (Q2 2027) Earnings Call Highlights: Record Revenue and FDA Review in Focus
2026-11-12 07:06 · Yahoo
Beyond Air (XAIR) Q2 2027 Earnings Call Transcript
2026-11-12 02:28 · Yahoo
Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026
2026-11-11 21:05 · Yahoo
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
2026-10-29 12:00 · Yahoo
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
2026-10-08 12:00 · Yahoo
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-02 12:00 · Yahoo
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
2026-08-25 11:00 · Yahoo
Beyond Air (XAIR) Q1 2027 Earnings Call Transcript
2026-08-14 03:58 · Yahoo
Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ...
2026-08-13 23:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.